CA3137559A1 - Compositions comprising non-crystalline forms of cannabidiol - Google Patents

Compositions comprising non-crystalline forms of cannabidiol Download PDF

Info

Publication number
CA3137559A1
CA3137559A1 CA3137559A CA3137559A CA3137559A1 CA 3137559 A1 CA3137559 A1 CA 3137559A1 CA 3137559 A CA3137559 A CA 3137559A CA 3137559 A CA3137559 A CA 3137559A CA 3137559 A1 CA3137559 A1 CA 3137559A1
Authority
CA
Canada
Prior art keywords
composition
cannabidiol
mass
percent
terpene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3137559A
Other languages
French (fr)
Inventor
Nixon MALCOLM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natural Extraction Systems LLC
Original Assignee
Natural Extraction Systems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/408,428 external-priority patent/US10993928B2/en
Application filed by Natural Extraction Systems LLC filed Critical Natural Extraction Systems LLC
Publication of CA3137559A1 publication Critical patent/CA3137559A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Various aspects of this patent document relate to (i) compositions comprising cannabidiol, which have either a freezing point or a glass-liquid transition temperature of less than the melting point of pure cannabidiol, (ii) containers that contain such compositions, and (iii) methods to manufacture cannabidiol products.

Description

COMPOSITIONS COMPRISING NON-CRYSTALLINE FORMS OF CANNABIDIOL
CROSS-REFERENCE TO RELATED APPLICATIONS
This patent application claims priority to U.S. Provisional Patent Application No. 62/839,564, filed April 26, 2019; U.S. Provisional Patent Application No. 62/845,231, filed May 8, 2019; U.S.
Patent Application No. 16/408,428, filed May 9, 2019; U.S. Provisional Patent Application No.
62/860,224, filed June 11, 2019; and U.S. Provisional Patent Application No.
62/942,442, filed December 2, 2019, each of which is incorporated by reference in its entirety.
BACKGROUND
Cannabidiol exists as a crystalline solid at room temperature, which has a melting point of 151 degrees Fahrenheit (66 degrees Celsius). Crystalline cannabidiol lacks robust bioavailability, for example, because the human body is incapable of melting it. The pharmaceutical EPIDIOLEX
contains cannabidiol dissolved in sesame seed oil to increase bioavailability.
Consumers also vaporize and inhale cannabidiol to increase bioavailability.
Cannabidiol crystallization confounds vaporization in electronic cigarettes and vaporizers because crystallization inhibits the flow of cannabidiol toward a heating element.
Prior art methods to inhibit the crystallization of cannabidiol for use in electronic cigarettes and vaporizers include the dissolution of cannabidiol in organic solvents such as propylene glycol and triglycerides. Organic solvents dilute the cannabidiol, however, and present unknown health risks.
Improved cannabidiol formulations are therefore desirable.
SUMMARY
Various aspects of this patent document relate to compositions comprising liquid cannabidiol, -- which have either a freezing point or a glass-liquid transition temperature of less than the melting point of pure cannabidiol. In preferred embodiments, the freezing point or the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
DETAILED DESCRIPTION
This patent document discloses that the melting point of cannabidiol can be lowered¨or eliminated¨by dissolving small amounts of specific solutes in liquid cannabidiol. The melting point of cannabidiol can be reduced to less than 70 degrees Fahrenheit (or less than 21 degrees Celsius), for example, to provide concentrated cannabidiol compositions that are liquids at room temperature. This discovery allows novel products including concentrated cannabidiol vape oil.
Various aspects of this patent document relate to a composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, in which:
the one or more solutes comprise a terpene and a terpene oxidation product;
the terpene is humulene; the terpene oxidation product is either bicyclohumuladiol, tricyclohumuladiol, tricyclohumuladiol II, humulenol II, humulene epoxide I, humulene epoxide II, or humulene epoxide III; the composition comprises the humulene and the terpene oxidation product at a ratio of at least 1:10 and no greater than 10,000:1 by mass; the cannabidiol is a liquid; the one or more solutes are dissolved in the cannabidiol; and either (i) the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature, or (ii) the composition has a glass-liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
In some preferred embodiments, the terpene oxidation product is bicyclohumuladiol.
In some preferred embodiments, the terpene oxidation product is tricyclohumuladiol.
In some preferred embodiments, the terpene oxidation product is tricyclohumuladiol II.
In some preferred embodiments, the terpene oxidation product is humulenol II.
In some preferred embodiments, the terpene oxidation product is humulene epoxide I.
In some preferred embodiments, the terpene oxidation product is humulene epoxide II.
In some preferred embodiments, the terpene oxidation product is humulene epoxide III.
Various aspects of this patent document relate to a composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein:
the one or more solutes comprise a terpene and a terpene oxidation product;
the terpene is beta-caryophyllene; the terpene oxidation product is caryophyllene oxide; the composition comprises the beta-caryophyllene and the caryophyllene oxide at a ratio of at least 1:10 and no greater than 10,000:1 by mass; the cannabidiol is a liquid; the one or more solutes are dissolved in the cannabidiol; and either (i) the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature, or (ii) the composition has a glass-
2 liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
Various aspects of this patent document relate to a composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein:
the one or more solutes comprise a terpene and a terpene oxidation product;
the terpene is alpha-bisabolol; the terpene oxidation product is either caryophyllene oxide or humulene epoxide II; the composition comprises the alpha-bisabolol and the terpene oxidation product at a ratio of at least 1:10 and no greater than 10,000:1 by mass; the cannabidiol is a liquid; the one or more solutes are dissolved in the cannabidiol; and either (i) the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature, or (ii) the composition has a glass-liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
Various aspects of this patent document relate to a composition, comprising (i) cannabidiol at a concentration of at least 50 percent and no greater than 99.5 percent by mass and (ii) one or more solutes selected from terpenes, terpene alcohols, and terpenoids at a combined concentration of at least 0.5 percent and no greater than 40 percent by mass, in which: the one or more solutes are dissolved in the cannabidiol; the composition has either a freezing point or a glass-liquid transition temperature; and the freezing point or the glass-liquid transition temperature is either (i) at least 50 degrees Fahrenheit less than the freezing point of pure cannabidiol or (ii) at least 27 degrees Celsius less than the freezing point of pure cannabidiol. In some preferred embodiments, the composition comprises the cannabidiol at a concentration of at least 65 percent and no greater than 99.5 percent by mass, and the composition comprises the one or more solutes at a combined concentration of at least 0.5 percent and no greater than 35 percent by mass.
In some specific preferred embodiments, the composition comprises the cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and the composition comprises the one or more solutes at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass.
In some very specific preferred embodiments, the composition comprises the cannabidiol at a concentration of at least 75 percent and no greater than 99.5 percent by mass, and the composition comprises the one or more solutes at a combined concentration of at least 0.5 percent and no greater than 25 percent by mass.
3 HO
.,_ HO
Formula I. Cannabidiol HO

li
4----...` 0 Formula II. Tetrahydrocannabinol HO
=0 Formula III. (6aS,10aR) Stereoisomer of Tetrahydrocannabinol Formula IV. Beta-Caryophyllene *
=
Formula V. Caryophyllene Oxide *
Formula VI. Humulene *

Flor,0 H
OH
Formula VII. Bicyclohumuladiol *
HO
4, H
HO i "
st.
Formula VIII. Tri cyclohumuladiol *
HO
H
....FA

44,*
HO*
Formula IX. Tricyclohumuladiol II *

Formula X. Humulene Epoxide I *
00'81*.
Formula XI. Humulene Epoxide II *
Formula XII. Humulene Epoxide III *

Formula XIII. Humulenol II *
HO
H 4111 00' Formula XIV. Alpha-Bisabolol *
HO
,0 Formula XV. Cannabichromene t Table I: Names of the Molecules of Formulas I-XV
Formula Common Name Chemical Name 2-[(1R,6R)-6-i sopropeny1-3 -methylcyclohex-2-en-l-y1]-I Cannabidiol
5-pentylbenzene-1,3-diol (6aR,10aR)-6,6,9-trimethy1-3 -penty1-6a,7,8,10a-II Tetrahydrocannabinol tetrahydro-6H-benzo[c]chromen-1-ol (6aS,10aR) (6aS,10aR)-6,6,9-trimethy1-3 -penty1-6a,7,8,10a-III Stereoisomer of tetrahydro-6H-benzo[c]chromen-1-ol Tetrahydrocannabinol (1R,4E,9S)-4,11,11-trimethy1-8-IV Beta-caryophyllene *
methylidenebicyclo[7.2.0]undec-4-ene (1R,4R,6R,10S)-4,12,12-trimethy1-9-methylene-5-V Caryophyllene oxide *
oxatricyclo[8.2Ø04'6]dodecane VI Humulene * (1E,4E,8E)-2,6,6,9-tetramethy1-1,4,8-cycloundecatriene (2R,9S)-1,5,8,8-tetramethylbicyclo[8.1.0]undec-5-ene-VII Bicyclohumuladiol *
2,9-diol (1R,2R,4R,5R,8S,9S)-4,8,11,11-VIII Tricyclohumuladiol *
tetramethyltricyclo[7.2Ø021undecane-5,8-diol (1S,2R,4R,5R,8S,9S)-4,8,11,11-IX Tricyclohumuladiol II *
tetramethyltricycIo[6.3Ø021undecane-5,9-diol (1S,4E,7E,11S)-1,5,9,9-tetramethy1-12-X Humulene epoxide I *
oxabicyclo[9.1.0]dodeca-4,7-diene (1R,3E,7E,11R)-1,5,5,8-tetramethy1-12-XI Humulene epoxide II *
oxabicyclo[9.1.0]dodeca-3,7-diene (1R,3E,7E,11R)-3,7 ,10,10-tetramethy1-12-XII Humulene epoxide III *
oxabicyclo[9.1.0]dodeca-3,7-diene Formula Common Name Chemical Name (1R,4Z,8Z)-6,6,9-trimethy1-2-methylene-4,8-XIII Humulenol II *
cycloundecadien-l-ol (1R,4Z,8Z)-6,6,9-trimethy1-2-methylene-4,8-XIV Alpha-Bisabolol *
cycloundecadien-l-ol 2-methy1-2-(4-methylpent-3-en-1-y1)-5-hydroxy-7-XV Cannabichromene penty1-2H-1-benzopyran * Formulas IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, and XIV depict stereochemistry, but each Common Name as used both in this patent specification and in the patent claims encompasses both the depicted stereochemistry of a Chemical Formula and each stereoisomer of a Chemical Formula because a probability distribution of each stereoisomer exists in natural products and because accredited cannabinoid testing laboratories generally do not distinguish stereoisomers;
t Formula XV does not depict stereochemistry, and "cannabichromene"
encompasses both stereoisomers of Formula XV.
In some embodiments, the composition has a freezing point; the composition lacks a glass-liquid transition temperature; and the freezing point is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
In some embodiments, the composition has a glass-liquid transition temperature; the composition lacks a freezing point; and the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
In some embodiments, the composition lacks crystals of cannabidiol.
In some embodiments, the composition comprises cannabidiol at a concentration of at least 75 percent and no greater than 99 percent by mass.
In some embodiments, the composition lacks tetrahydrocannabinol at a concentration greater than 0.3 percent by mass.
In some embodiments, the composition comprises tetrahydrocannabinol at a concentration greater than 0.3 percent by mass; the tetrahydrocannabinol is dissolved in the cannabidiol; and the composition comprises the cannabidiol and the tetrahydrocannabinol at a ratio of at least 3:1 and no greater than 200:1 by mass.
In some embodiments, the composition comprises (6aS,10aR)-6,6,9-trimethy1-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol at a concentration of at least 0.05 percent and no greater than 5 percent by mass, in which the (6aS,10aR)-6,6,9-trimethy1-3-penty1-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol is dissolved in the cannabidiol.
In some embodiments, the composition comprises molecules having a boiling point of less than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95 percent by mass.
In some embodiments, the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5 percent by mass.
In some preferred embodiments, the composition lacks propylene glycol.
In some preferred embodiments, the composition lacks triglycerides.
In some preferred embodiments, the composition lacks phospholipids.
In some preferred embodiments, the composition lacks waxes.
In some embodiments, the composition is a liquid.
In some embodiments, the composition has a viscosity, and the viscosity is less than 100 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius. In some specific embodiments, the viscosity is at least 50 millipascal-seconds and no greater than 50 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
In some embodiments, the one or more solutes comprise one or more of alpha-bisabolol, alpha-phellandrene, alpha-pinene, alpha-terpinene, alpha-terpineol, beta-caryophyllene, beta-pinene, borneol, cadinene, camphene, camphor, caryophyllene oxide, citral, citronellol, delta-3-carene, eucalyptol, eugenol, gamma-terpinene, geraniol, guaiol, humulene, isopulegol, limonene, linalool, myrcene, nerol, nerolidol, ocimene, para-cymene, phytol, pulegone, terpineol, terpinolene, and valencene at a combined concentration of at least 0.5 percent and no greater than 40 percent by mass. In some specific embodiments, the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of at least 0.5 percent and no greater than 40 percent by mass.
In some preferred embodiments, the one or more solutes comprise alpha-bisabolol.
In some preferred embodiments, the one or more solutes comprise beta-caryophyllene.
In some preferred embodiments, the one or more solutes comprise caryophyllene oxide.
In some preferred embodiments, the one or more solutes comprise humulene.

In some very specific embodiments, the composition comprises cannabidiol at a concentration of at least 65 percent and no greater than 99 percent by mass; the composition lacks crystals of cannabidiol; the composition lacks tetrahydrocannabinol at a concentration greater than 0.3 percent by mass; the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of at least 0.5 percent and no greater than 35 percent by mass; the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95 percent by mass; the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration of greater than 5 percent by mass; the composition has a glass-liquid transition temperature;
the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius; the composition lacks a freezing point; the composition is a liquid; the composition has a viscosity;
and the viscosity is at least 50 millipascal-seconds and no greater than 50 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
In some very specific embodiments, the composition comprises cannabidiol at a concentration of at least 65 percent and no greater than 99 percent by mass; the composition lacks crystals of cannabidiol; the composition comprises tetrahydrocannabinol at a concentration of greater than 0.3 percent by mass; the tetrahydrocannabinol is dissolved in the cannabidiol; the composition comprises cannabidiol and tetrahydrocannabinol at a ratio of at least 3:1 and no greater than 200:1 by mass; the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of at least 0.5 percent and no greater than 35 percent by mass; the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95 percent by mass; the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5 percent by mass; the composition has a glass-liquid transition temperature;
the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius; the composition lacks a freezing point; the composition is a liquid; the composition has a viscosity;
and the viscosity is at least 50 millipascal-seconds and no greater than 50 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
In some embodiments, the composition comprises cannabichromene at a concentration of at least 0.1 percent and no greater than 10 percent by mass. In some specific embodiments, the composition comprises cannabichromene at a concentration of at least 0.81 percent and no greater than 8.1 percent by mass. In some very specific embodiments, the composition comprises cannabichromene at a concentration of at least 1.94 percent and no greater than 6.92 percent by mass. The combination of cannabichromene and one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products is more effective at reducing the freezing point of liquid cannabidiol than the one or more solutes alone.
In some embodiments, the composition comprises cannabigerol at a concentration of at least 0.1 percent and no greater than 10 percent by mass. In some specific embodiments, the composition comprises cannabigerol at a concentration of at least 0.81 percent and no greater than 8.1 percent by mass. In some very specific embodiments, the composition comprises cannabigerol at a concentration of at least 1.94 percent and no greater than 6.92 percent by mass.
Various aspects of this patent document relate to a method to manufacture a cannabidiol product, comprising (i) providing a starting composition comprising liquid cannabidiol; and (ii) dissolving one or more terpenes, terpene alcohols, terpenoids, or terpene oxidation products in the liquid cannabidiol to produce a composition described anywhere in this patent document.
Various aspects of this patent document relate to a container comprising (i) a heating element and (ii) a chamber that contains at least 2 milligrams and no greater than 2 grams of a composition described anywhere in this patent document, wherein the heating element is in thermal communication with the composition. In some specific embodiments, the container is configured to be connected to a battery such that the battery and the heating element are in electrical communication that allows the transfer of electrical energy from the battery to the heating element;
the heating element is operable to convert the electrical energy into sufficient heat energy; and the sufficient heat energy is sufficient to heat the composition to a temperature greater than the boiling point of the cannabidiol. In some very specific embodiments, the container is connected to the battery such that the battery and the heating element are in electrical communication.
Various aspects of this patent document relate to a method to manufacture a cannabidiol product, comprising (i) providing a composition comprising cannabidiol and one or more solutes, wherein the cannabidiol is a liquid, and the one or more solutes are dissolved in the cannabidiol;
(ii) providing a starting container comprising a heating element; and (iii) inserting at least 2 milligrams and no greater than 2 grams of the composition into the starting container to produce a container described anywhere in this patent document.
Various aspects of this patent document relate to a method to manufacture a cannabidiol product, comprising (i) providing a starting composition comprising liquid cannabidiol; (ii) dissolving one or more terpenes, terpene alcohols, terpenoids, or terpene oxidation products in the liquid cannabidiol to produce a composition described anywhere in this patent document; (iii) providing a starting container comprising a heating element; and (iv) inserting at least 2 milligrams and no greater than 2 grams of the composition into the starting container to produce a container described anywhere in this patent document.
The following example provides a framework to implement certain aspects of the disclosure, and this example does not limit the scope of this patent document or any claim that matures from the disclosure of this patent document.
Example 1. Production of compositions comprising cannabidiol that do not crystallize Cannabinoids were extracted from organic industrial hemp using the system described in PCT
Patent Application Publication No. 2016/161420 Al to produce crude industrial hemp extract comprising 65-70% cannabidiol; 5-10% terpenes, terpene alcohols, and terpenoids; 2-3%
tetrahydrocannabinol; and other volatile molecules including waxes and phospholipids. The crude industrial hemp extract formed crystals of cannabidiol when stored at room temperature for 24 hours.
The cannabinoids of the crude industrial hemp extract were separated from other molecules by distillation in a VTA Short Path Distillation Plant VKL 70 (Verfahrenstechnische Anlagen GmbH
& Co. KG, Germany) to produce a cannabinoid distillate comprising approximately 90%
cannabidiol and 5% tetrahydrocannabinol. 10 grams of the cannabinoid distillate was combined with 0.1 grams of a terpene, terpene alcohol, and terpenoid blend obtained from True Terpenes (Oregon, USA) with heating to produce a liquid composition. The blend contained beta-caryophyllene (41%), humulene (18%), linalool (13%), limonene, alpha-bisabolol, nerolidol, beta-pinene, citronellol, fenchol, and other molecules at lower concentrations.
The liquid composition was stored at room temperature for 1 year with intermittent exposure to light and air, and the composition produced no detectable crystals. Cooling the liquid below room temperature vitrified the composition into a glass without any detectable crystal formation.
This example demonstrates that small amounts of terpenes, terpene alcohols, and terpenoids can provide robust stabilization of cannabidiol in a liquid state and inhibit crystal formation over commercially-relevant timeframes, even when subjected to chemical stress, provided that lipids that comprise fatty acids are removed from the liquid state.

Claims (26)

What is claimed is:
1. A composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein:
the one or more solutes comprise a terpene and a terpene oxidation product;
the terpene is humulene;
the terpene oxidation product is either bicyclohumuladiol, tricyclohumuladiol, tricyclohumuladiol II, humulenol II, humulene epoxide I, humulene epoxide II, or humulene epoxide III;
the composition comprises the humulene and the terpene oxidation product at a ratio of at least 1:10 and no greater than 10,000:1 by mass;
the cannabidiol is a liquid;
the one or more solutes are dissolved in the cannabidiol; and either:
the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature; or the composition has a glass-liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
2. A composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein:
the one or more solutes comprise a terpene and a terpene oxidation product;
the terpene is beta-caryophyllene;
the terpene oxidation product is caryophyllene oxide;
the composition comprises the beta-caryophyllene and the caryophyllene oxide at a ratio of at least 1:10 and no greater than 10,000:1 by mass;
the cannabidiol is a liquid;
the one or more solutes are dissolved in the cannabidiol; and either:
the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature; or the composition has a glass-liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
3. A composition, comprising (i) cannabidiol at a concentration of at least 70 percent and no greater than 99.5 percent by mass, and (ii) one or more solutes selected from terpenes, terpene alcohols, terpenoids, and terpene oxidation products at a combined concentration of at least 0.5 percent and no greater than 30 percent by mass, wherein:
the one or more solutes comprise a terpene and a terpene oxidation product;
the terpene is alpha-bisabolol;
the terpene oxidation product is either caryophyllene oxide or humulene epoxide II;
the composition comprises the alpha-bisabolol and the terpene oxidation product at a ratio of at least 1:10 and no greater than 10,000:1 by mass;
the cannabidiol is a liquid;
the one or more solutes are dissolved in the cannabidiol; and either:
the composition has a freezing point of less than 21 degrees Celsius, and the composition lacks a glass-liquid transition temperature; or the composition has a glass-liquid transition temperature of less than 21 degrees Celsius, and the composition lacks a freezing point.
4. A composition, comprising cannabidiol at a concentration of 50% to 99.5% by mass and one or more solutes selected from terpenes, terpene alcohols, and terpenoids at a combined concentration of 0.5% to 40% by mass, in which:
the one or more solutes are dissolved in the cannabidiol;
the composition has either a freezing point or a glass-liquid transition temperature; and the freezing point or the glass-liquid transition temperature is either at least 50 degrees Fahrenheit less than the freezing point of pure cannabidiol or at least 27 degrees Celsius less than the freezing point of pure cannabidiol.
5. The composition of any one of claims 1-4, in which:
the composition has a freezing point;
the composition lacks a glass-liquid transition temperature; and the freezing point is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
6. The composition of any one of claims 1-4, in which:
the composition has a glass-liquid transition temperature;
the composition lacks a freezing point; and the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius.
7. The composition of any one of claims 1-6, in which the composition lacks crystals of cannabidiol.
8. The composition of any one of claims 1-7, in which the composition comprises cannabidiol at a concentration of 75% to 99% by mass.
9. The composition of any one of claims 1-8, in which the composition lacks tetrahydrocannabinol at a concentration greater than 0.3% by mass.
10. The composition of any one of claims 1-8, in which:
the composition comprises tetrahydrocannabinol at a concentration greater than 0.3% by mass;
the tetrahydrocannabinol is dissolved in the cannabidiol; and the composition comprises cannabidiol and tetrahydrocannabinol at a ratio of 3:1 to 200:1 by mass.
11. The composition of any one of claims 1-10, comprising (6aS,10aR)-6,6,9-trimethy1-3-penty1-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol at a concentration of 0.05% to 5% by mass, in which the (6aS,10aR)-6,6,9-trimethy1-3-penty1-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen- 1 -ol is dissolved in the cannabidiol.
12. The composition of any one of claims 1-11, in which the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95% by mass.
13. The composition of any one of claims 1-12, in which the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5% by mass.
14. The composition of any one of claims 1-13, in which the composition is a liquid.
15. The composition of any one of claims 1-14, in which the composition has a viscosity, and the viscosity is less than 100 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
16. The composition of claim 15, in which the viscosity is 50 millipascal-seconds to 50 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
17. The composition of any one of claims 1-16, in which the one or more solutes comprise one or more of alpha-bisabolol, alpha-phellandrene, alpha-pinene, alpha-terpinene, alpha-terpineol, beta-caryophyllene, beta-pinene, borneol, cadinene, camphene, camphor, caryophyllene oxide, citral, citronellol, delta-3-carene, eucalyptol, eugenol, gamma-terpinene, geraniol, guaiol, humulene, isopulegol, limonene, linalool, myrcene, nerol, nerolidol, ocimene, para-cymene, phytol, pulegone, terpineol, terpinolene, and valencene at a combined concentration of 0.5% to 40% by mass.
18. The composition of any one of claims 1-17, in which the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of 0.5% to 40% by mass.
19. The composition of any one of claims 1-18, in which:
the composition comprises cannabidiol at a concentration of 65% to 99% by mass;
the composition lacks crystals of cannabidiol;
the composition lacks tetrahydrocannabinol at a concentration greater than 0.3% by mass;
the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of 0.5% to 35% by mass;
the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95%
by mass;

the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5% by mass;
the composition has a glass-liquid transition temperature;
the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius;
the composition lacks a freezing point;
the composition is a liquid; and the composition has a viscosity, and the viscosity is 50 millipascal-seconds to 50 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
20. The composition of any one of claims 1-19, in which:
the composition comprises cannabidiol at a concentration of 65% to 99% by mass;
the composition lacks crystals of cannabidiol;
the composition comprises tetrahydrocannabinol at a concentration greater than 0.3% by mass;
the tetrahydrocannabinol is dissolved in the cannabidiol;
the composition comprises cannabidiol and tetrahydrocannabinol at a ratio of 3:1 to 200:1 by mass;
the one or more solutes comprise one or more of alpha-bisabolol, beta-caryophyllene, guaiol, humulene, limonene, myrcene, and terpinolene at a combined concentration of 0.5% to 35% by mass;
the composition comprises molecules having a boiling point lower than either 360 degrees Fahrenheit or 182 degrees Celsius at a combined concentration of at least 95%
by mass;
the composition lacks propylene glycol, glycerol, triglycerides, phospholipids, fatty acids, and waxes at a combined concentration greater than 5% by mass;
the composition has a glass-liquid transition temperature;
the glass-liquid transition temperature is less than either 70 degrees Fahrenheit or 21 degrees Celsius;
the composition lacks a freezing point;
the composition is a liquid; and the composition has a viscosity, and the viscosity is 50 millipascal-seconds to 50 pascal-seconds at a temperature of either 70 degrees Fahrenheit or 21 degrees Celsius.
21. The composition of any one of claims 1-20, comprising cannabichromene at a concentration of at least 0.1 percent and no greater than 10 percent by mass.
22. The composition of any one of claims 1-21, comprising cannabigerol at a concentration of at least 0.1 percent and no greater than 10 percent by mass.
23. A method to manufacture a cannabidiol product, comprising:
providing a starting composition comprising liquid cannabidiol; and dissolving one or more terpenes, terpene alcohols, terpenoids, or terpene oxidation products in the liquid cannabidiol to produce a composition according to any one of claims 1-22.
24. A container, comprising (i) a heating element and (ii) a chamber that contains at least 2 milligrams and no greater than 2 grams of a composition according to any one of claims 1-22, wherein the heating element is in thermal communication with the composition.
25. A method to manufacture a cannabidiol product, comprising:
providing a composition comprising cannabidiol and one or more solutes, wherein the cannabidiol is a liquid, and the one or more solutes are dissolved in the cannabidiol;
providing a starting container comprising a heating element; and inserting at least 2 milligrams and no greater than 2 grams of the composition into the starting container to produce the container of claim 24.
26. A method to manufacture a cannabidiol product, comprising:
providing a starting composition comprising liquid cannabidiol;
dissolving one or more terpenes, terpene alcohols, terpenoids, or terpene oxidation products in the liquid cannabidiol to produce a composition;
providing a starting container comprising a heating element; and inserting at least 2 milligrams and no greater than 2 grams of the composition into the starting container to produce the container of claim 24.
CA3137559A 2019-04-26 2020-04-24 Compositions comprising non-crystalline forms of cannabidiol Pending CA3137559A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962839564P 2019-04-26 2019-04-26
US62/839,564 2019-04-26
US201962845231P 2019-05-08 2019-05-08
US62/845,231 2019-05-08
US16/408,428 2019-05-09
US16/408,428 US10993928B2 (en) 2019-04-26 2019-05-09 Compositions comprising non-crystalline forms of cannabidiol
US201962860224P 2019-06-11 2019-06-11
US62/860,224 2019-06-11
US201962942442P 2019-12-02 2019-12-02
US62/942,442 2019-12-02
PCT/US2020/029745 WO2020219829A1 (en) 2019-04-26 2020-04-24 Compositions comprising non-crystalline forms of cannabidiol

Publications (1)

Publication Number Publication Date
CA3137559A1 true CA3137559A1 (en) 2020-10-29

Family

ID=72941782

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3137559A Pending CA3137559A1 (en) 2019-04-26 2020-04-24 Compositions comprising non-crystalline forms of cannabidiol

Country Status (2)

Country Link
CA (1) CA3137559A1 (en)
WO (1) WO2020219829A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085724B2 (en) * 2010-09-17 2015-07-21 Lubri3ol Oilfield Chemistry LLC Environmentally friendly base fluids and methods for making and using same
CA2996626A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
RU2717782C2 (en) * 2015-07-30 2020-03-25 Сумитомо Раббер Индастриз, Лтд. Rubber mixture
CA3017696A1 (en) * 2016-03-16 2017-09-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition
CA3018951A1 (en) * 2016-03-28 2017-10-05 To Pharmaceuticals Llc Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract

Also Published As

Publication number Publication date
WO2020219829A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
CN103589515B (en) Supercritical carbon dioxide extraction method of high-purity lavender essential oil
US20210267935A1 (en) Cannabis product
US20200102283A1 (en) Methods for Obtaining Purified Cannabis Extracts and THCA Crystals
US10864459B2 (en) Methods to produce cannabinoid products from decarboxylated cannabinoid extracts
US20230002340A1 (en) Separation of cannabinoids from mixtures thereof by distillation
US20240342130A1 (en) Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
Rustaiyan et al. Volatile constituents of Ballota aucheri Boiss., Stachys benthamiana Boiss. and Perovskia abrotanoides Karel. growing wild in Iran
Kumar et al. Getting fragrance from plants
Batool et al. Extraction, production and analysis techniques for menthol: A review
CA3137559A1 (en) Compositions comprising non-crystalline forms of cannabidiol
US10993928B2 (en) Compositions comprising non-crystalline forms of cannabidiol
CN104173224A (en) Ethanol-free perfume
CA3221865A1 (en) Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products
Tohar et al. Chemical composition of the essential oils of four Plumeria species grown on Peninsular Malaysia
WO2023212170A1 (en) Endogenous stabilization of cannabinoids
Dogan et al. Essential oil composition of the fruits of Seseli resinosum Freyn et Sint. and Seseli tortuosum L. growing in Turkey
US11465957B1 (en) Methods and systems for crystallizing and isolating individual cannabinoids
AU2022376837A1 (en) Systems and methods for producing hemp extracts and compositions
Orji et al. Phytochemical Profiling and GC-MS Analysis of Lantana camara Leaf Extract.
Vernin et al. GC/MS analysis of the volatile constituents of Corymbia citriodora Hook. from Réunion Island
Jeppesen et al. Chemical composition of the essential oil from nine medicinal plants of the Wakhan corridor, Afghanistan
WO2020123383A1 (en) Compositions with novel cannabinoid and terpene profiles
CA3178778A1 (en) Apparatus for cannabinol generation and methods of using the same
de Lima et al. Chemistry, Biological Activities, and Uses of Copaiba Oil Resins
Delange et al. Determination by GC-MS of the hexane extract components from Malvaviscus penduliflorus flowers growing in Cuba

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240424